New methods to assess the effectiveness of virus-based therapies
Nanopore Methods for Determining Capsid Viability
This study is working on a new technology to help make gene therapy safer and more effective by figuring out which virus particles are ready to deliver treatment and which ones aren't, so patients can get better therapies for their conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10693909 on NIH RePORTER |
What this research studies
This research focuses on developing advanced nanopore technology to accurately determine the viability of adeno-associated virus (AAV) vectors, which are increasingly used in gene therapy. By using synthetic pore-based sensors, the project aims to differentiate between full and empty viral capsids, which is crucial for ensuring the quality and effectiveness of these therapeutic agents. The researchers will also explore high-throughput analysis methods to streamline the production process of AAVs, ultimately enhancing their application in treating various diseases. Patients may benefit from improved therapies that are more effective and safer due to better quality control of these viral vectors.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with conditions that may be treated using AAV-based gene therapies.
Not a fit: Patients who do not have access to AAV-based therapies or those whose conditions are not suitable for such treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and reliable gene therapies for patients.
How similar studies have performed: Other research has shown promise in using nanopore technology for various applications, indicating potential success for this approach in the context of AAV characterization.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Ritola, Kimberly — Univ of North Carolina Chapel Hill
- Study coordinator: Ritola, Kimberly
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.